BRISBANE, Calif. (AP) _ Aimmune Therapeutics Inc. (AIMT) on Thursday reported a loss of $66.9 million in its fourth quarter.

The Brisbane, California-based company said it had a loss of $1.06 per share.

The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.05 per share.

For the year, the company reported that its loss widened to $248.5 million, or $3.97 per share.

Aimmune Therapeutics shares have dropped 27% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $24.43, a fall of roughly 2% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AIMT at https://www.zacks.com/ap/AIMT

Automated Insights, source Associated Press News